Table 2 Expression of ARK5 and SIRT3 in RCC and non-neoplastic cases
From: Evaluation of ARK5 and SIRT3 expression in renal cell carcinoma and their clinical significance
|  | RCC ( n  = 58) (%) | Non-neoplastic ( n  = 30) (%) | Test | P value |
|---|---|---|---|---|
Expression | Â | Â | Fisher Exact Test | 0.057 |
 ARK5 negative | 3 (5.2%) | 6 (2%) | ||
 ARK5 positive | 55(94.8%) | 24 (98%) | ||
Intracellular localization | Â | Â | Fisher Exact Test | 0.001** |
 ARK5 cytoplasmic | 19 (34.5%) | 24 (100%) | ||
 ARK5 nucleocytoplasmic | 36 (65.4%) | 0 (00%) | ||
H-score | 164.5 ± 55.651 | 113.3 ± 65.7 | Mann–Whitney | 0.001** |
Expression | Â | Â | Fisher Exact Test | 0.002* |
SIRT3 negative | 14 (24.14%) | 18 (6%) | ||
SIRT3 positive | 44 (75.9%) | 12 (94%) | ||
H- score | 134.6 ± 81.2 | 59.7 ± 76.3 | Mann–Whitney | 0.001** |